<DOC>
	<DOC>NCT00171717</DOC>
	<brief_summary>The trial is conducted in patients who have received a liver transplant, were prescribed tacrolimus to prevent organ rejection and developed diabetes from 3 month post-transplantation onwards. The goal of the trial is to assess the percentage of patients in whom diabetes will resolve 6 month after conversion from tacrolimus to cyclosporine micro-emulsion as measured by a fasting blood glucose &lt; 1,26 g/l without the need of hypoglycemic treatment.</brief_summary>
	<brief_title>Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Patients who have received a first liver transplantation and who are 18 to 70 year old Patients who are treated with tacrolimus posttransplant for at least 3 months and for a maximum of 36 months Patients without any known diabetes before transplantation and in whom diabetes mellitus was diagnosed for the first time at least 3 months posttransplantation Exclusion Criteria Retransplantation or multiorgan transplantation, Diabetes before the transplantation, Type I diabetes mellitus. Other protocoldefined inclusion / exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Cyclosporine, liver transplantation, maintenance, diabetes</keyword>
</DOC>